News
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
MIRA Pharmaceuticals presents preclinical results at Pain Therapeutics Summit showcasing that Ketamir-2 achieves 100% reversal of neuropathic pain. The innovative therapy targets NMDA receptors for enhanced efficacy -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
MIRA Pharmaceuticals announces progress in clinical development planning for novel oral ketamine analog, emphasizing early efficacy signal detection in humans by 2025. IND filing on schedule for December 2024 with focus on neuropathic pain treatment -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
MIRA Pharmaceuticals, Inc. selects neuropathic pain as the primary indication for its novel oral ketamine analog, Ketamir-2, targeting neurologic disorders. Pre-IND meeting with FDA anticipated in Nov 2024 -
-
